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"Many people ignore the fact that the incidence of abortion
reflects the state of contraception."'
"The real problem with emergency postcoital contraception is
not its failure rate or its side effects but the fact that so few
women and adolescents who have had unprotected inter-
course actually use it."
2
I. INTRODUCTION
Each year in the United States, 3.5 million women uninten-
tionally become pregnant.3 Moreover, approximately 1.5 mil-
lion abortions are performed annually,4 making the United
States' abortion rate one of the highest among Western coun-
tries.' Meanwhile, the number of women and children living
below the poverty level continues to increase. 6 These facts indi-
cate that women urgently need additional methods of fertility
control. For many women who unintentionally become preg-
nant, the consequences are not disastrous. For these women,
the decision whether to have an abortion, give the child up for
adoption, or keep the child may be clear and have no long-term
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1. Carl Djerassi, The Bitter Pill, 245 SCIENCE 356, 358 (1989).
2. Anna Glasier et al., Mifepristone (RU 486) Compared with High-Dose Estrogen
and Progestogen for Emergency Postcoital Contraception, 327 NEw ENG. J. MED. 1041,
1044 (1992).
3. James Trussell et al., Emergency Contraceptive Pills: A Simple Proposal to
Reduce Unintended Pregnancies, 24 FAM. PLAN. PEsp. 269 (1992).
4. Djerassi, supra note 1, at 356.
5. Stanley K Henshaw, Induced Abortion: A World Review, 1990, 22 FAM. PLAN.
PERsp. 76, 78 (1990). According to statistics compiled by Henshaw, among countries
with complete statistics, only Japan, South Korea, Singapore, China, the Soviet Union,
Turkey, Hungary, Czechoslovakia, Bulgaria, Yugoslavia, and Cuba have abortion rates
higher than that of the United States. Id.
6. U.S. BuRaAu OF THE CENSUS, STATISTICAL ABSTRACT OF THE UNITED STATES:
1992 458 (1992). According to the Census Bureau statistics, in 1979 there were 13.5
million families headed by a female householder living below the poverty level. Id. In
1990, the number had risen to 17.2 million. Id.
164 University of Puget Sound Law Review
adverse effects. However, many women face an agonizing
dilemma when none of these three options appears viable.
Postcoital contraceptives, which act after fertilization but
before a fertilized egg implants in the womb,7 offer women
greater control over their own fertility. For example, many
unintended pregnancies result from contraceptive failure, such
as a condom breaking.8 In these cases, a woman may realize
she is at risk of becoming pregnant and use a postcoital contra-
ceptive to prevent an unwanted pregnancy. One such contra-
ceptive, popularly known as the "morning-after pill" because it
must be administered within seventy-two hours of unprotected
intercourse, has been available for some time but has not been
widely used.9
A significant development in postcoital contraception
occurred in 1992 when scientists reported in The New England
Journal of Medicine that RU-486, the so-called "abortion pill,"
was highly effective as a postcoital contraceptive.' ° RU-486, a
synthetic drug most widely used as an abortifacient, 11 was
developed in France more than a decade ago.' 2 Because the
drug is highly effective in terminating early pregnancies, 13 it
has been extremely controversial in this country.14 The heated
political debate over abortion, strident opposition from right-to-
life groups, and the antiabortion stance of the Reagan and Bush
administrations 5 have prevented RU-486 from being submitted
to the United States Food and Drug Administration (FDA) for
7. Postcoital Contraception-An Appraisal, 1976 POPULATION REP. 141.
8. Trussell et al., supra note 3, at 269.
9. See infra notes 105-120 and accompanying text. Unprotected intercourse refers
to sexual intercourse during which no contraceptive methods are used, putting the
woman at risk of becoming pregnant.
10. See Glasier et al., supra note 2, at 1041.
11. "Abortifacient" is defined as "[a]n agent that produces abortion." STEDMAN'S
MEDICAL DICTIONARY 3 (25th ed. 1990). "Abortion" is defined as "[g]iving birth to an
embryo or fetus prior to the stage of viability at about 20 weeks of gestation." Id.
12. ETIENNE-EMILE BAULIEU & MoaRT ROSENBLUM, THE "ABORTION PLL" 16-17
(1991) [hereinafter THE ABORTION PILL]. The drug takes its name from the French
company that developed it, Roussel-Uclaf. The original number of the molecular
compound is RU 38486; mifepristone is the generic name. Etienne-Emile Baulieu, RU-
486 as an Antiprogesterone Steroid; From Receptor to Contragestion and Beyond, 262
JAMA 1808, 1810 (1989) [hereinafter Contragestion].
13. Robin Herman & Fern Schumer Chapman, The Politics of the Abortion Pill,
WASH. PosT, Oct. 3, 1989, (Health Section), at 13.
14. Id. at 12.
15. Joseph Palca, The Pill of Choice?, 245 SCIENCE 1319, 1321 (1989); see also infra
notes 33-34 and accompanying text.
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approval. 1 6 However, new abortion policies instituted by the
Clinton administration appear to be paving the way for submis-
sion and ultimate approval of the drug.' v This Comment argues
that if RU-486 were approved as a postcoital contraceptive
rather than as an abortifacient, the drug would be of greater
overall benefit to women seeking to control their fertility.
FDA approval of RU-486 as a postcoital contraceptive
would be of greater overall benefit to women than approval of
the drug as an abortifacient in a number of ways. First, women
would have a broader range of birth control options. Dr. Eti-
enne-Emile Baulieu, the developer of RU-486, has pointed out
that women may need several different forms of birth control
during their fertile lives, because factors relevant to contracep-
tion, including changes in age and in the status of their per-
sonal lives, vary over a woman's lifetime.' Under certain
circumstances, a woman may find invaluable a method of birth
control that allows decision making to occur after intercourse.
The second major benefit to women of FDA approval of RU-
486 as a postcoital contraceptive is that fewer women will
require abortions or even face the decision whether to abort.
Abortion may raise significant medical and moral issues that
are implicated only slightly, if at all, by methods of fertility con-
trol that act before a pregnancy has been established. In the
United States, the vast majority of abortions are performed
legally during the first trimester,' 9 and no significant complica-
tions result.2 ° However, abortions performed illegally or in the
later stages of pregnancy may be associated with serious health
risks and even death.2 ' In addition, many women would not
16. See Palca, supra note 15, at 1321. See generally William Regelson, RU 486:
How Abortion Politics Have Impacted on a Potentially Useful Drug of Broad Medical
Application, 35 PERSP. BioLOGY & MED. 330 (1992).
17. See John Schwartz, U.S. Group to Get Rights to Produce 'Abortion Pill,' WASH.
POST, Apr. 21, 1993, at Al.
18. Contragestion, supra note 12, at 1808.
19. Council on Scientific Affairs, American Medical Association, Induced
Termination of Pregnancy Before and After Roe v. Wade, 268 JAMA 3231, 3233 (1992)
[hereinafter Induced Termination]; Abortion Surveillance: Preliminary Analysis-
United States, 1986 and 1987, 262 JAMA 2076 (1989) [hereinafter Abortion
Surveillance]. In 1986 and 1987, as in previous years, nearly 90% of legal abortions
were performed during the first 12 weeks of gestation. Id.
20. Induced Termination, supra note 19, at 3235. The National Abortion
Federation in Washington, D.C. estimates that in 1990 there was one complication per
1,000 abortions. Id.
21. Id. at 3238. Between 1972 and 1974, the number of deaths per 100,000 illegal
abortions was approximately eight times greater than for legal abortions. W. Cates, Jr.
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choose abortion under any circumstances because they regard it
as taking life. Even among women who believe that abortion
must remain legal and available, support for abortion may
decrease as pregnancy advances and the fetus begins to look
more and more like a person. Reducing the occurrence of
unwanted pregnancies will therefore free women from facing
what for many is an anguishing moral and ethical dilemma.
Although the need for abortion is unlikely to be completely
eradicated, there is little doubt that wider availability and use
of postcoital contraceptive methods could help to reduce signifi-
cantly the number of abortions performed each year in the
United States. A 1989 survey of two hundred Planned
Parenthood patients who had abortions showed that thirty per-
cent had realized right away that they might be pregnant and
would have preferred the morning-after pill to an abortion if
they had been aware of the treatment.22 In the Netherlands,
where postcoital contraceptives have been available for years,
the treatment is cited as the leading reason for an abortion rate
one fifth of that of the United States.23
In addition to benefitting women, FDA approval of RU-486
as a postcoital contraceptive will also benefit the drug's manu-
facturers and marketers. Such a strategy will allow both the
drug's French manufacturer, Roussel-Uclaf, and companies in
the United States to avoid much of the abortion controversy
that has surrounded RU-486. Many people who are vehemently
opposed to abortion will continue to oppose RU-486 as a
postcoital contraceptive, both because of its potential use in ter-
minating established pregnancies and because of a belief that
even an unimplanted fertilized egg deserves the same protec-
tion as a fetus or a person.24 However, fewer people oppose
birth control than oppose abortion, and the legal right to pri-
vacy in choosing to use birth control has been firmly established
in this country since the Supreme Court's decision in Griswold
v. Connecticut.25 In upholding this right, courts have not distin-
guished between birth control methods that act before or after
& R.W. Rochat, Illegal Abortions in the United States: 1972-1974, 8 FAM. PLAN. PERSP.
86, 92 (1976).
22. Jan Hoffman, The Morning-After Pill: A Well Kept Secret, N.Y. TIMES, Jan. 10,
1993, (Magazine), at 12-13.
23. Id.
24. See Irwin Arieff, Doctors Say 'Morning-After" Contraception Available in U.S.,
REuTmss, Mar. 6, 1989, available in LEXIS, Nexis Library, Reuters File.
25. 381 U.S. 479 (1965).
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fertilization. 26 Thus, those involved in manufacturing, distrib-
uting, and marketing RU-486 should focus on its use as a birth
control method and work to educate the public about this new
use of the drug. This strategy will reduce vulnerability to boy-
cotts or other politically motivated obstacles that could impair
wide distribution of a much-needed new drug. With this fear
assuaged, manufacturers and marketers will be in a position to
maximize profits from licensing the drug in the United States.
Finally, the medical community will benefit if RU-486 is
approved as a postcoital contraceptive. Doctors will have
another option available to offer women seeking to control their
fertility. Moreover, doctors who oppose abortion would proba-
bly be more comfortable prescribing RU-486 as a postcoital con-
traceptive because the medical profession generally views
pregnancy as beginning with successful implantation, not with
fertilization. 2 7 Reducing the need for abortion will allow medi-
cal resources to be directed toward other pressing health
problems, such as AIDS and other sexually transmitted dis-
eases. Furthermore, minimizing the abortion controversy at
the regulatory level will mean that the drug is available to doc-
tors sooner than it otherwise would be. Because a drug
approved by the FDA for one use may be prescribed for other
uses,28 doctors will gain access to RU-486 for testing in a wide
range of applications including, and in addition to, fertility
control.
To support the argument that RU-486 should be approved
as a postcoital contraceptive, Part II of this Comment examines
the background and development of the drug, the controversy it
has engendered, and the drug's recently discovered contracep-
tive potential. Part III provides a short look at the process by
which the FDA approves new drugs and discusses how RU-486
would likely progress through this process. Part IV begins by
examining the current postcoital contraceptive regimen, the
morning-after pill, and discusses the obstacles associated with
the use and the availability of this method. Part IV then dis-
cusses the legal, medical, and policy reasons for approving RU-
486 as a postcoital contraceptive.
26. See infra notes 178-195 and accompanying text.
27. See infra notes 128-133 and accompanying text.
28. See infra notes 95-100 and accompanying text.
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II. RU-486: "THE MORAL PROPERTY OF WOMEN"
A. Background
RU-486 was approved for use by the French government in
1988.29 Although the drug has now been used by more than
100,000 French women,3 ° its introduction was not without con-
siderable controversy. Almost immediately after the drug was
licensed, Roussel-Uclaf withdrew it in the face of threatened
boycotts and opposition from the Catholic church.31 However,
the French government intervened two days later, stating that
governmental approval had made RU-486 "the moral property
of women" and that if Roussel-Uclaf did not market the drug,
the rights would be given to another company.2
In the United States, introduction of RU-486 was blocked in
large part by the Bush administration. 33 However, the Clinton
administration promptly set about dismantling the anti-abor-
tion policies of the previous two administrations.3 4 Further-
more, the medical profession and the public have indicated for
some time that the drug would be well received. For example,
in June 1990, the American Medical Association adopted a reso-
lution supporting the drug's clinical application in abortion.35
Similarly, in February 1991, the American Association for the
Advancement of Science went on record favoring broad medical
availability of RU-486. 36 In addition, fifty-nine percent of those
responding to a recent Harris poll favored making the drug
available, and thirty-seven percent said they would be willing to
try it. 3 7 The following section describes how the drug works and
its current use and effectiveness.
29. THE ABORTION PILL, supra note 12, at 41.
30. Etienne-Emile Baulieu, Updating RU 486 Development, 20 LAW MED. &
HEALTH CARE 154 (1992).
31. THE ABORTION PILL, supra note 12, at 43-44.
32. Id. at 49.
33. David A. Grimes & Rebecca J. Cook, Mifepristone (RU 486)-An Abortifacient
To Prevent Abortion?, 327 NEW ENG. J. MED. 1088, 1089 (1992).
34. For example, the Clinton adminstration lifted restrictions on abortion
counselling at federally funded clinics and on fetal tissue research. President Clinton
also instituted a review of the ban on importing RU-486. Clinton Signs Memoranda on
Abortion, Fetal Tissue, REUTERS, Jan. 22, 1993, available in LEXIS, Nexis Library,
Reuters File [hereinafter Clinton Signs Memoranda]; Roussel-Uclaf Waits for Word
from U.S., REUTERS, Jan. 25, 1993, available in LEXIS, Nexis Library, Reuters File.
35. Regelson, supra note 16, at 335.
36. Id.
37. Virginia Kallianes, Bitter Pill for Abortion Foes, NEWSDAY, July 21, 1989,
(Viewpoints Section), at 78.
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B. Current Use as an Abortifacient
RU-486 works by binding to progesterone receptors in the
uterus, thus inhibiting the activity of progesterone, a hormone
essential to maintain pregnancy. 38 Progesterone prepares the
uterus for implantation of the fertilized egg. After implanta-
tion, progesterone sustains the embryo until the placenta has
formed. 9 Without progesterone, the uterine lining breaks
down and the uterus secretes prostaglandins, which produce
muscle contractions that expel the fertilized egg or fetus.40 To
induce abortion during the early weeks of pregnancy,41 a single
600 mg dose of the drug is given orally.42 Researchers found
that administering a synthetic prostaglandin, which causes
uterine contractions, increased the effectiveness of RU-486.43
According to Roussel-Uclaf, the drug is eighty-five percent effec-
tive when taken alone.44 In combination with a prostaglandin,
however, RU-486 is successful in causing abortion in ninety-six
percent of cases.45
Its success rate is impressive, but RU-486 is not without
side effects. It may cause nausea, cramping, and bleeding.46 In
addition, about four percent of abortions are incomplete and
require surgical intervention.4 7 Some concern about the drug's
effects on children born as a result of an unsuccessful abortion
has been expressed,48 but studies on monkeys have suggested
there is no risk to the fetus if pregnancy continues.49 Studies
report that women who had successful abortions using RU-486
have returned to normal ovulatory cycles.5 0 In addition, several
women who later became pregnant and chose to continue their
pregnancies gave birth to normal children. 1
38. Rebecca Cook, Antiprogestin Drugs: Medical and Legal Issues, 21 FAM. PtAN.
PERSP. 267 (1989).
39. Id.
40. Herman & Chapman, supra note 13, at 12.
41. RU-486 is effective as an abortifacient only up to the seventh week of
pregnancy. See id. at 13.
42. See Contragestion, supra note 12, at 1812.
43. Herman & Chapman, supra note 13, at 13.
44. Id.
45. Id.
46. Id. at 13.
47. Id. at 12.
48. Id.




170 University of Puget Sound Law Review
In addition to its use as an abortifacient, RU-486 has been
demonstrated to be useful in treating various illnesses and dis-
orders.52 Furthermore, the drug has potential uses as a regular
contraceptive53 and a means to induce labor or to expel fetuses
that have died in utero during the later stages of pregnancy.54
However, in the words of Dr. Baulieu, 'RU-486's great promise
is in preventing pregnancy in the first place."55 The next sec-
tion further explores that potential.
C. Preventing Pregnancy with RU-486
In October 1992, The New England Journal of Medicine
published the results of a study in which women who had had
unprotected intercourse were given either a 600 mg dose of RU-
486 or the morning-after pill estrogen and progestogen regi-
men.56 No statistically significant difference in the failure rates
was seen.5
7
The difference in side effects was significant, however.
More than one third of those receiving RU-486 had no symp-
toms, compared to only thirteen percent of those who received
the estrogen and progestogen regime.58 Furthermore, the inci-
dence of nausea, vomiting, headache, and breast tenderness
among those in the RU-486 group was substantially lower.5 9
These results are strengthened by another study involving a
randomized trial of three emergency birth control treatments:
52. See Regelson, supra note 16, at 331.
53. Joannie Schrof, Reproduction Showdown, U.S. NEws & WoRLD REP., Mar. 22,
1993, at 32, 34. Dr. Baulieu suggests that the most feasible way to use RU-486 as a
regular contraceptive would be to take a low dose of the drug throughout the month. Id.
Such a method would closely resemble the current birth control pill regimen, but
without the steady stream of hormones and their side effects. European studies have
also indicated that RU-486 may be effective as a once-a-month pill, taken shortly after
ovulation or shortly before a woman expects her menstrual period. Id. The advantages
of this use are that the monthly intake of medication is reduced, it is more convenient
than other contraceptives, and it is more flexible because if a woman is not sexually
active in a given month, she does not need to take the drug. The disadvantage of this
method is that because menstrual cycles are irregular, the timing of the dose would be
difficult to pinpoint. Id.
54. Herman & Chapman, supra note 13.
55. THE ABORmON PiLL, supra note 12, at 174.
56. Glasier et al., supra note 2, at 1041-42.
57. Id. at 1042. Of 402 women treated with RU-486, none became pregnant; there
were four pregnancies among 398 women treated with the standard regimen. Id.
58. Id. at 1043.
59. Id. In particular, 17% of women in the standard regimen group reported severe




the standard estrogen and progestogen morning-after pill,
another birth control pill called danocrine, and RU-486.60
Women who received RU-486 and danocrine experienced much
less nausea and vomiting, and none of the women who took RU-
486 became pregnant."
According to the New England Journal study, the only
apparent disadvantage of RU-486 is that more women who
received the drug experienced a delay in the onset of their next
menstrual period.6 2 This delay may add to a woman's anxiety.
However, the likelihood of late menses can be predicted based
on where the woman was in her cycle at the time of treatment.6 3
In addition, extremely sensitive home pregnancy tests are now
available and can be used to reassure women that they are not
pregnant.64
The results of this study indicate that RU-486 should be
approved by the FDA as a postcoital contraceptive. In an edito-
rial accompanying the New England Journal study, leading
medical and legal researchers argued that by depriving women
who need emergency contraception of this drug, the Bush
administration was perpetrating a "national disgrace."65 The
authors of the editorial noted that objections to FDA approval of
RU-486 as an abortifacient "do not relate to pursuing approval
for its use as a postcoital contraceptive agent."66 Part III of this
Comment addresses the process by which new drugs obtain reg-
ulatory approval and looks at how RU-486 would likely progress
through this process.
III. RU-486 AND THE FDA
A. The FDA Approval Process
The Federal Food, Drug, and Cosmetic Act of 193867
required only that drugs introduced into interstate commerce
be safe .6  The 1962 amendments to the Act added the require-
60. Anne M.C. Webb et al., Comparison of Yuzpe Regimen, Danazol, and
MiFepristone (RU 486) in Oral Postcoital Contraception, 205 BmRr. MED. J. 927 (1992).
61. Id. at 929.
62. Glasier et al., supra note 2, at 1043.
63. Id. at 1044.
64. Grimes & Cook, supra note 33, at 1089.
65. Id. The study was published in October 1992, during the final months of the
Bush administration.
66. Id.
67. 21 U.S.C. §§ 301-1509 (1988).
68. Id. § 355(a)-(b).
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ment that a drug must also be effective. 9 The Act states that
new drugs may not be introduced into interstate commerce
unless approved by the FDA,70 and it sets forth the require-
ments for a sponsor seeking approval of a new drug.7'
The first step of this process is for a drug's sponsor to sub-
mit an Investigational New Drug application (IND),72 which
contains the results of animal studies on the drug's pharmaco-
logical and toxicological effects. 73 Next, if the FDA approves the
IND application, human testing is carried out in three phases.7 4
Phase one studies are conducted on patients or healthy volun-
teers and are designed to determine how the drug affects
humans, what its side effects are, and how effective it appears
to be.75 In phase two, controlled clinical studies are conducted
to evaluate the drug's effectiveness in patients with the disease
or condition for which the drug is indicated.76 Phase three
involves expanded controlled and uncontrolled studies that are
intended to gather more information about safety and effective-
ness, which is needed to evaluate the benefits and risks of the
drug.77 All the information gathered from these clinical trials is
then submitted to the FDA in the sponsor's New Drug Applica-
tion (NDA), which forms the basis for the FDA's scrutiny of the
drug.78 In addition to the clinical test results, the NDA must
include information about the drug's composition, toxicology,
behavior in the body, manufacturing, processing, and packag-
ing.79 The sponsor must also specify the conditions the drug is
being promoted to treat.8 0
Under the Act, the FDA has 180 days from the date an
NDA is filed to approve or to reject the application.8 ' In prac-
69. Drug Amendments of 1962, Pub. L. No. 87-781, § 102(b), 76 Stat. 780, 781
(codified at 21 U.S.C. § 355(b)(1)(a) (1988) (stating that a new drug application must
include "full reports of investigations, whether such drug is effective in use")).
70. 21 U.S.C. § 355(a) (1988).
71. Id. § 355(b).
72. 21 C.F.R. § 312.20 (1993).
73. Id. § 312.23(aX5)(ii).
74. Id. § 312.21(a)-(c).
75. Id. § 312.21(a).
76. Id. § 312.21(b).
77. Id. § 312.21(c).
78. Id. § 314.50.
79. Id. § 314.50(dXi)-(vi) (listing and describing the specific FDA requirements).
See generally Dixie Farley, How FDA Approves New Drugs, 21 FDA CONSUMER 7, 9
(1987).
80. 21 C.F.R. § 314.50(cX2)(ii) (1993).
81. Id. § 314.100(a).
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tice, however, extensions are the rule. The average approval
time for a new drug is two years.8 2 The FDA may contact the
sponsor or investigators at any time during its review to discuss
problems with the data. 3 Moreover, the agency requires the
sponsor to report promptly and to investigate any serious and
unexpected "adverse drug experience." 4
At the FDA, INDs and NDAs are classified to determine
review priority on the basis of the drug's chemical type and
potential benefit.8 5 Drugs featuring an active ingredient never
before marketed in this country and representing an important
therapeutic gain are given the highest priority review."
Because of its new molecular structure and potential for wide-
spread use, RU-486 would likely receive high review priority.
B. RU-486: Outlook and Strategies for FDA Approval
In December 1992, the FDA indicated that European
clinical trials of RU-486 may be sufficient for the agency to con-
duct its review process.8 ' A 1985 revision of NDA regulations
allows approval on the basis of foreign studies alone. 8 Thus,
the company ultimately selected to market the drug could com-
plete safety trials and submit an NDA before the end of 1993.89
The time required for agency review would be shortened to
between four and six months.9 ° However, this expedited pro-
cess is based on the assumption that approval will be sought for
RU-486 as an abortifacient.9 Clinical studies of the drug as a
postcoital contraceptive are much fewer in number, and it is not
clear whether the studies would be sufficient to satisfy the
FDA's requirements.9 2 However, even if more clinical trials
were required, it is unlikely that this additional time will signif-
82. Farley, supra note 79, at 9.
83. 21 C.F.R. § 314.102 (1993); Farley, supra note 79, at 11.
84. 21 C.F.R. § 314.80(cXi) (1993).
85. Farley, supra note 79, at 12.
86. Id. AIDS drugs are an exception to this ranking system; they are given review
priority above all other drugs. Id.
87. FDA: RU-486 Could be OKd Soon in U.S., Cm. Tam., Dec. 17, 1992, at 10
(quoting letter from Carol Scheman, Deputy FDA Commissioner, to Rep. Ron Wyden).
88. Farley, supra note 79, at 10.
89. Schrof, supra note 53, at 32.
90. Id.
91. See id.
92. There are numerous clinical studies of RU-486 in early pregnancy. See THE
ABORTION PiLL, supra note 12, at 208-11; Contragestion, supra note 12. In contrast, the
Author is aware of only two clinical studies of RU-486 as a postcoital contraceptive. See
Glasier et al., supra note 2; Webb et al., supra note 60.
1731993]
174 University of Puget Sound Law Review [Vol. 17:163
icantly delay entry of RU-486 into the American market. The
delay would be offset by time saved in resolving the political
controversy surrounding the characterization of RU-486 as an
abortifacient.
The FDA approves about seventy-five percent of all NDAs
submitted.93 Approval of an NDA opens the door for the spon-
sor to market a drug as soon as its production and distribution
systems are in place.94 Once a drug has been approved for a
specific medical use, a doctor may prescribe it for any purpose,
whether approved for that purpose or not.95 A 1975 case, F.T.C.
v. Simeon Management Corp.,9" established that the FDA does
not have jurisdiction to regulate the administration of a drug by
a doctor.97 A doctor prescribing drugs for nonapproved uses is a
common medical practice.9 8 However, a drug company cannot
promote, advertise, or label a drug for non-approved purposes.99
Although there is little incentive for a manufacturer to seek
approval for a new use, drugs are often readily available for
nonapproved uses.100
At least one commentator believes that RU-486 can meet
the FDA's efficacy and safety standards for use as an abortifa-
cient.10 Alternatively, the drug's sponsor could seek FDA
approval for a use unrelated to fertility control, thus enabling
doctors to prescribe the drug for use both as an abortifacient
and a contraceptive. 102 However, this strategy would not solve
many of the problems posed by the current lack of a widely
available postcoital contraceptive. 103 Because extensive
clinical trials would be required, a greater delay would occur
before the drug became available for any use. In addition, fears
about incurring liability would make doctors reluctant to pre-
scribe RU-486 for fertility-related uses if the drug were
93. Farley, supra note 79, at 13.
94. Id.
95. Marshall Kapp, Prescribing Approved Drugs For Nonapproved Uses:
Physician's Disclosure Obligations to Their Patients, 9 LAw ME). & HEALTH CARE 20
(1981).
96. 391 F. Supp. 697 (N.D. Cal. 1975).
97. Id. at 706.
98. Kapp, supra note 96, at 20.
99. Hoffman, supra note 22, at 14.
100. Kapp, supra note 95, at 21.
101. Nancy Buc, RU 486, the FDA and Free Enterprise, 20 LAW MED. & HELTH
CARE 224 (1992).
102. Valerie Cotler, Note, The FDA, Contraception, and RU 486, 12 WoME'ds RTs.
L. REP. 123, 135 (1990).
103. See infra notes 141-157 and accompanying text.
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approved only for a completely different use. 10 4 And, as Part IV
explains, RU-486 would likely remain unavailable as a
postcoital contraceptive at federally funded clinics.
With this background in mind, Part IV makes the argu-
ment that RU-486 should be submitted and approved as a
postcoital contraceptive. To illustrate the need for a new drug
for this use, Part IV begins by examining the current emergency
contraceptive regimen, the morning-after pill.
IV. WHY SEEK APPROVAL OF RU-486 AS A
POSTCOITAL CONTRACEPTIWE?
A. Problems with Current Availability and Use of Postcoital
Contraceptives: The Morning-After Pill
1. Existing Postcoital Contraceptives
Although emergency contraception has been used for at
least two thousand years, it was not until the 1960s that practi-
cal methods evolved. 10 5 In 1973, diethylstilbestrol (DES), a syn-
thetic estrogen, became the only postcoital contraceptive ever to
be given FDA approval. 106 Despite questions about its safety
and efficacy, DES is still approved for use as an emergency con-
traceptive for rape victims. 10
7
Today, the most widely used postcoital contraceptive regi-
men consists of a concentrated dose of Ovral, a combined
estrogen and progestogen birth control pill.108 Four tablets are
prescribed, with two taken immediately and two more taken
104. Cotler, supra note 102, at 135.
105. Grimes & Cook, supra note 33, at 1088.
106. Hoffman, supra note 22, at 30. Between 1947 and 1971, DES was prescribed
to pregnant women to prevent spontaneous abortion (expulsion of the fetus during the
first 12 weeks of gestation) and miscarriage (fetal expulsion between the 12th and 28th
weeks of gestation). Corey Scott Cramin, Note, Emotional Distress Damages for
Cancerphobia: A Case for the DES Daughter, 14 PAC. L.J. 1214, 1218 (1983). In 1971,
several studies were published linking the use of DES by pregnant women to vaginal
cancer in their daughters. Id. The FDA then suspended the use of DES by pregnant
women. The FDA now requires a warning label stating that use of the drug by pregnant
women increases the risk of vaginal abnormalities in their offspring. Id. at 1219.
107. Cotler, supra note 102, at 126. For a discussion of the medical studies of DES
and the case law arising from its use by pregnant women, see generally Naomi Sehiner,
Comment, DES and a Proposed Theory of Enterprise Liability, 46 FORDHAm L. REviEw
963 (1978).
108. Arieff, supra note 24. Ovral, the most extensively used birth control pill in the
world today, is approved by the FDA for use as a regular oral contraceptive. Id. When
used in this way, one tablet is taken each day for three weeks, and menstruation occurs
during the fourth week.
1993]
176 University of Puget Sound Law Review
twelve hours later. 109 The pills must be taken within seventy-
two hours of unprotected intercourse. 110 A concentrated dose of
birth control pills taken after unprotected intercourse prevents
pregnancy by temporarily disrupting a woman's hormonal pat-
terns. 11 By altering the release of hormones from the ovaries,
the hormones in the pills disturb the development of the uterine
lining and disrupt the transport of a fertilized ovum through
the fallopian tubes." 2 Thus, depending on how soon after
unprotected intercourse a woman takes the morning-after pill,
the treatment either prevents fertilization of the egg or stops
the fertilized egg from implanting. 11 3
Although studies have found that Ovral used in this way is
ninety-eight percent effective in preventing pregnancy, 1 4 other
studies have challenged the efficacy of this regimen." 5 Many
studies base their success rates on the total number of women
included in the study rather than the number of women poten-
tially pregnant, leading to charges that the failure rate of
postcoital contraception is grossly underestimated." 6 In
response to this criticism, further studies maintain that emer-
gency contraceptive regimen can be expected to reduce the
expected number of pregnancies by seventy-five percent.
1 7
Ovral is not the only postcoital contraceptive currently in
use. Recently, a second hormonal regimen consisting of 600 mg
of danocrine has been employed.1" However, the results on the
efficacy of this method have been mixed, with some studies
reporting failure rates as high as ten percent." 9 In addition,
postcoital insertion of an IUD is extremely effective in prevent-
ing pregnancy, but this method is invasive, associated with side
109. Id.
110. Id.
111. Trussell et al., supra note 3, at 269.
112. Id.
113. Hoffman, supra note 22, at 12.
114. Arieff, supra note 24.
115. Louise Silvestre et al., Postcoital Contraception: Myth or Reality?, 338 LANCET
39, 41 (1991).
116. Id. The likelihood that a woman who has had unprotected intercourse is at
risk of pregnancy varies substantially depending on when in her menstrual cycle the
intercourse occured. For example, a woman's chance of becoming pregnant on her most
fertile day is only about 25%. Hoffman, supra note 22, at 13.
117. Trussell et al., supra note 3, at 269.
118. Id.
119. Id.; see also Glasier et al., supra note 2, at 1041.
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effects, and can be used only by women who have had at least
one child.1
20
2. "Contraception" Versus "Contragestion"
Because postcoital contraception acts after fertilization, Dr.
Baulieu, the developer of RU-486, has suggested the term "con-
tragestion" to distinguish these methods from contraception,
which for most people is synonymous with preventing fertiliza-
tion.121 One important difference between the two "contrages-
tives" discussed here is that RU-486 may be used as either a
regular monthly contraceptive or as emergency birth control.
The morning-after pill is used strictly as an emergency treat-
ment.1 22 To understand the status of, and obstacles to, the use
of the morning-after pill, this Comment explores some consider-
ations that apply to both emergency or regular use of a
contragestive.
In 1989, a prominent contraception researcher ranked a
once-a-month menstruation-inducing pill second on a priority
list of new contraceptive methods. 123 The researcher, Dr. Carl
Djerassi, stated that such a menses inducer could become the
single most effective method for reducing the forty million to
fifty million abortions performed annually in the world.124 For
a variety of reasons, however, contraceptive research in this
country has come to a virtual standstill.125 Of the nine major
pharmaceutical companies conducting research and develop-
ment in contraception in 1970, only one was still involved in
that field in 1987.126 Today, the United States government
120. Glasier et al., supra note 2, at 1041; Grimes & Cook, supra note 33, at 1088.
121. Contragestion, supra note 12, at 1813. Dr. Baulieu explains that
contraception" is a contraction of "contra-conception." Similarly, the word he has
coined, "contragestion," is a contraction of 'contra-gestation." Id.
122. Arieff, supra note 24; see also infra note 206 and accompanying text.
123. Djerassi, supra note 1, at 358-59. First on Dr. Djerassi's list of new
contraceptive methods was a new spermicide with antiviral properties. Id. at 358.
124. Id. at 359.
125. Dr. Djerassi attributes the halt of contraceptive research and development to
three causes: (1) reduced funding; (2) the Reagan administration's policy of preventing
government agencies from supporting contraception research; and (3) the fact that
developing countries have focused their efforts to control population growth on issues
such as education and optimum use of existing birth control methods, rather than the
search for new contraceptive methods. Id. at 358. Dr. Djerassi also points out that
infertility, rather than contraception, is currently the more popular area of human
reproductive biology for scientists to explore. Id.
126. Id. at 357.
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spends less on contraceptive research in a year than the
Defense Department spends on defense in fifteen minutes.
127
One of the obstacles to the development of contragestives
lies in the tension between medical and moral definitions of
pregnancy. The medical profession views pregnancy as begin-
ning when implantation is complete.' 28 Implantation is a pro-
cess that takes about a week and does not begin until five to six
days after fertilization. 129 Thus, fertilization is not the "unique
determining event in the conception of a new human being."
3 0
Dr. Baulieu, for example, views the generation of human life as
a continuous process.'"' The view of fertilization as a process
rather than an event is particularly compelling because a large
number of fertilized eggs fail to implant, and many embryos are
spontaneously aborted before they have developed into a
fetus.' 32 In fact, between twenty-two percent and thirty-one
percent of conceptions end in spontaneous abortion before or
after implantation. 133
On the other hand, the moral viewpoint asks not only when
a pregnancy has been established, but also the more difficult
question of when a new life can be said to exist. Basically, there
are three positions: (1) Life begins at conception.13 1 (2) Life
begins sometime during pregnancy.13 5 (3) Life does not begin
127. Cotler, supra note 102, at 131 (citing NEWSDAY, Jan. 12, 1979, at 77).
128. See Grimes & Cook, supra note 33, at 1089. The definition of pregnancy as
beginning with completed implantation has been adopted by the American College of
Obstetricians and Gynecologists. Cook, supra note 38, at 267.
129. Grimes & Cook, supra note 33, at 1089.
130. Id.
131. Contragestion, supra note 12, at 1813.
132. Cook, supra note 38, at 267.
133. Allen Wilcox et al., Incidence of Early Loss of Pregnancy, 319 NEw ENG. J.
MED. 189, 192-93 (1988). Dr. Wilcox reported that 22% of all early established
pregnancies detected by the presence of a hormone did not survive to the stage of being
recognized by a conventional pregnancy test. Combining these early losses with losses
that occurred later among recognized pregnancies resulted in an overall loss rate of
31%. Id.
134. Don Colburn, A Morning-After Pill; New Study Says RU-486 Works Better
Than Current Methods, WASH. PosT, Oct. 13, 1992, (Health section), at 7. Many
antiabortion groups such as Right to Life take the view that life begins with conception.
Richard Glasow, education director of the National Right to Life Committee, has stated,
"The union of the sperm and the ovum is the beginning of human life." Id. This view is
also reflected in the language of some state abortion statutes. See infra notes 175-186
and accompanying text.
135. See Grimes & Cook, supra note 33, at 1089. The view that life begins when
implantation is complete is widely held by the medical and scientific communities. Id.
Courts have also taken the view that life begins during pregnancy, without specifying
an exact point. See infra part IV.B.
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until birth.'1 6 Antiabortion groups, which generally follow the
first view, have opposed research and design of postcoital con-
traceptives because these methods act to prevent implantation
of a fertilized ovum. 137 As Dr. Albert Yuzpe, the developer of
the most widely used morning-after pill regimen, has stated, "A
contraceptive method that exerts its effects after fertilization
has occurred is for some unacceptable.
" 138
The fact that Ovral is widely available as a regular birth
control pill has somewhat diffused opposition. Antiabortion
groups have acknowledged that Ovral's availability as a regular
birth control pill makes preventing the pill's use as a postcoital
contraceptive virtually impossible. 139 Thus, if a new drug, such
as RU-486, were approved and marketed specifically as a
postcoital contraceptive, it would be considerably more vulnera-
ble to such opposition because it acts after fertilization. How-
ever, the education director of National Right to Life has
predicted that if the proponents of RU-486 successfully identify
the drug with contraception rather than solely with abortion,
opposition from the right-to-life movement could be seen as
reactionary. 140
3. Obstacles to the Use of Current Postcoital
Contraceptive Methods
FDA approval of RU-486 as a postcoital contraceptive
would remove many existing obstacles to the use of a postcoital
contraceptive. The biggest problem with the current postcoital
contraceptive regimen is the lack of knowledge about the treat-
ment. A recent New York Times Magazine article called the
morning-after pill "the best-kept contraceptive secret in
America.""' Although it is widely prescribed on college cam-
puses, the morning-after pill is still largely unknown to teenag-
ers and women in their thirties and forties. 4 2 Many
gynecologists do not even know about the regimen, although it
136. David Brushwood, Must a Catholic Hospital Inform a Rape Victim of the
Availability of the "Morning-After Pill"?, 47 Am. J. HosP. PHAImAcY 395, 396 (1990).
137. Cotler, supra note 102, at 131.
138. Arieff, supra note 24.
139. Id.
140. Sarah Ricks, The New French Abortion Pill: The Moral Property of Women, 1
YALE J.L. & FEmIuSM 75, 93 n.90 (1989).
141. Hoffman, supra note 22, at 12.
142. Id.
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has been the standard of care for rape victims in hospital emer-
gency rooms for at least a decade. 1
43
Several factors account for the relative obscurity and inac-
cessibility of postcoital contraception. First, many health care
practitioners are reluctant to prescribe the morning-after pill
because they fear that the high dose of hormones could have
adverse health effects.'" While the treatment is generally con-
sidered safe, some practitioners take the view that the risk of
pregnancy from one act of unprotected intercourse is not signifi-
cant enough to disrupt a woman's hormones. 4 5 Moreover, the
side effects of the treatment can be severe. More than one half
of the women who take the morning-after pill experience nau-
sea, headaches, and breast tenderness. About one fifth suffer
from vomiting as well.' 46
Second, the manufacturers of birth control pills have not
applied for FDA approval to market their products as emer-
gency contraceptives, and it is unlikely they will do so.147 The
disincentive is largely financial. The approval process is likely
to take an average of five years and cost tens of millions of dol-
lars.1 48 Because postcoital contraception involves a one-time
use of only four to eight pills, it is far less lucrative than regular
oral contraceptives, which a woman takes daily for three out of
every four weeks. 149 In addition, federal regulations have been
widely interpreted as requiring contraceptive drugs and devices
provided by federally financed family planning clinics 150 to be
approved by the FDA for the use prescribed. 15  Thus, the
143. Id. at 14-15.
144. Trussell et al., supra note 3, at 270.
145. Hoffman, supra note 22, at 30.
146. Glasier et al., supra note 2, at 1043.
147. Hoffman, supra note 22, at 30.
148. Id.
149. Id.
150. Title X provides federal grants for family planning services. 42 U.S.C. § 300(a)
(1988).
151. W. ARCHER, OFFICE OF POPULATION AFFAIRS, DEP'T OF HEALTH AND HUMAN
SERVS., PROHIBITION ON THE USE OF DEPO-PROVERA IN TITLE X FAMILY PLANNING
PROJECTS, PROGRAM INSTRUCTION SERIES OPA-91-1 (May 10, 1991). A 1991
memorandum from the Deputy Assistant Secretary for Population Affairs to regional
health administrators stated, "It is longstanding policy of the Office of Population
Affairs that contraceptive drugs and devices provided, either directly or through
referral, by Title X supported family planning projects must have been approved for
contraceptive purposes by the Food and Drug Administration." Id. The regulations
state that 'lelach project supported under this part must: (1) Provide a broad range of
acceptable and effective medically approved family planning methods... and services."
42 C.F.R. § 59.5(aXl) (1992) (emphasis added).
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morning-after pill is unavailable at clinics that receive federal
funding under Title X. 112 This means that millions of low-
income women and teenagers are denied access to this method
of postcoital contraception.1
3
Third, the fear of incurring liability may deter doctors from
prescribing emergency contraceptives, even though a drug
approved by the FDA for one use may legally be prescribed for
non-approved uses.1 5 4 Damage awards in birth defect cases are
among the highest in medical malpractice lawsuits. 5 5 Dam-
ages have been awarded even where a product was employed for
its FDA-approved use and where no link had been established
between the product and birth defects. 156 For example, in 1986,
a court awarded $4.7 million to a woman who claimed that her
child's birth defects were caused by the spermicide Ortho-
Gynol.15
7
For these reasons, the morning-after pill is inadequate to
meet women's needs for postcoital contraception. If approved as
a postcoital contraceptive, RU-486 would help significantly in
meeting this need, thereby reducing the need for abortion.
With the need for such a new drug established, Section B dis-
cusses how this new contragestive would fit into the existing
legal framework governing birth control and abortion.
B. Griswold, Casey, and the Right to Privacy: Where Does
RU-486 Fit In?
RU-486 as a postcoital contraceptive is conceptually similar
to two currently used methods of birth control, the morning-
after pill and the IUD, because both of these may act after fer-
tilization.'5 8 Although the IUD and RU-486 differ in their
chemical and mechanical effects, they are substantially similar
from a legal standpoint because both interfere with the nurtur-
ing uterine environment so that pregnancy does not con-
tinue.'5 9 It is important to note that the morning-after pill and
the IUD are not generally considered abortifacients. Although
152. Hoffman, supra note 22, at 14.
153. Id.
154. Trussel et al., supra note 3, at 270; see supra notes 95-100 and accompanying
text.
155. Hoffman, supra note 22, at 30.
156. Id.
157. Wells v. Ortho Pharmaceutical Corp., 788 F.2d 741, 747 (11th Cir.), cert.
denied, 479 U.S. 950 (1986).
158. See supra notes 108-120 and accompanying text.
159. Ricks, supra note 140, at 80.
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many antiabortionists oppose any method that may act after
fertilization, their opposition has not coalesced as a drive to ban
either the UD or the morning-after pill.
160
This conceptual similarity suggests that RU-486 should be
treated the same as the IUD and the morning-after pill for legal
and regulatory purposes if RU-486 is submitted only for
postcoital contraceptive use. Whether the drug is considered a
contraceptive or an abortifacient is important because of the dif-
ferences between the legal treatment of the right to contracep-
tion and the right to abortion. The constitutional right not to
procreate by choosing to use contraception was established in
Griswold v. Connecticut161 and further strengthened by Eisen-
stadt v. Baird1 62 and Carey v. Population Services Interna-
tional.'6 3 Grounded in privacy, this fundamental right not to
procreate remains relatively uncontroversial and unchallenged.
On the other hand, the right to choose abortion has become
increasingly controversial in the twenty years since the
Supreme Court held in Roe v. Wade' 64 that a constitutionally
protected right to abortion exists, at least until the point of fetal
viability. 165
Recent abortion cases have underscored that Roe's founda-
tion is shaky. For example, in Webster v. Reproductive Health
Services, 16 6 the Court upheld a Missouri statute limiting deliv-
ery of abortion services in the third trimester.167 Similarly, in
the most recent case, Planned Parenthood of Southeastern
Pennsylvania v. Casey, 168 the Court narrowly upheld a woman's
basic right to seek abortion, but clarified the Webster Court's
holding that a state may regulate that choice even in the early
stages of pregnancy. 16 9 Under Casey, a state statute regulating
abortion may be constitutional so long as it does not impose an
undue burden on a woman's right to choose abortion. 1 70 Chal-
lenges aimed at clarifying what constitutes an undue burden
are sure to follow. However, because Casey did not overturn
160. Cook, supra note 38, at 270.
161. 381 U.S. 479 (1965).
162. 405 U.S. 438 (1972).
163. 431 U.S. 678 (1977).
164. 410 U.S. 113 (1973).
165. Id. at 164-65.
166. 492 U.S. 490 (1989).
167. Id. at 519-20.
168. 112 S. Ct. 2791 (1992).
169. Id. at 2818.
170. Id. at 2820.
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Roe, it now appears likely that some level of constitutional pro-
tection for the right to choose abortion will remain.
Because RU-486 is effective as an abortifacient only during
the very early stages of pregnancy, its use as an abortifacient
would probably be safe from governmental interference even
under the narrowing of Roe that has occurred with Webster and
Casey. One commentator has suggested that even if RU-486
was approved as a monthly contraceptive, its use would likely
be governed by federal abortion law rather than by contracep-
tive law because of the drug's potential to be used intentionally
as an abortifacient. 171 However, the same commentator recog-
nized a slight possibility that the drug would be placed under
regulations on contraception. 172 Thus, if RU-486's proponents
focus solely on the drug's use as a postcoital contraceptive, the
result may be to put RU-486 firmly in the area of private con-
traceptive decision making that has enjoyed undiminished pro-
tection under Griswold and its progeny.
From the standpoint of increasing women's birth control
options, the consequences of the FDA approving RU-486 as a
contraceptive would be dramatic. 173 Federal regulation of con-
traceptives is limited to their initial entry into the market and
to the requirement that some forms be prescribed by a doctor. 174
Thus, approval of RU-486 as a postcoital contraceptive is the
best means of ensuring that the drug will remain available to
women for contraceptive use, even if future court decisions fur-
ther restrict the right to abortion.
With the regulatory framework of abortion somewhat clari-
fied, the most pressing legal problem surrounding abortion is
also a philosophical one. In state legislatures and the courts,
the narrow view that life begins at fertilization appears to be on
a collision course with itself because courts since Roe have
refused to address the question of when life begins. For exam-
ple, the preamble to the Missouri statute upheld in Webster
states that "[t]he life of each human being begins at concep-
tion."175 However, the Court did not consider whether this lan-
guage would render the statute unconstitutional as infringing
on the right to birth control. Instead, the Court upheld the pre-
amble on the grounds that it merely stated a value judgment
171. Ricks, supra note 140, at 82.
172. Id. at 76.
173. Id. at 81.
174. Id.
175. Mo. REV. STAT. § 1.205.1 (1) (1986).
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and did not regulate abortion. 176 The Webster Court rejected
the plaintiffs' claims that the preamble's definition of life could
prevent doctors from prescribing birth control methods that act
after fertilization, such as the IUD. 17
7
Indeed, despite legislative determinations such as Mis-
souri's, which are completely inconsistent with medical defini-
tions of when life begins, no court has ever held that the
morning-after pill or the IUD is abortion, even though that con-
clusion would appear to be logically dictated by such statutory
language. 178 In at least two cases, lower federal courts have
confirmed the view that birth control methods that act after fer-
tilization are not abortion. In Margaret S. v. Edwin
Edwards, 79 Louisiana's abortion statute was challenged as
being impermissibly vague because it defines abortion as "the
deliberate termination of human pregnancy after fertiliza-
tion ... "180 The plaintiffs, which included a number of health
clinics and doctors, charged that, under this definition, birth
control methods such as the IUD or the morning-after pill
would be outlawed as abortifacients.' 8' The court held that the
definition was no more vague than that in most abortion stat-
utes and stated that "[a]bortion, as it is commonly understood,
does not include the IUD, the 'morning-after' pill, or for exam-
ple, birth control pills."1 8 2 Thus, the statute was upheld
because the court essentially disregarded its literal meaning.
However, another court struck down similar provisions con-
tained in an Illinois abortion law. In Charles v. Carey, 183 plain-
tiffs claimed that the statute's definition of "abortifacient" was
overbroad and impermissibly infringed on the right to birth con-
trol.' 84 The statute defined "abortifacient" as "any instrument,
medicine, drug, or any other substance or device which is
known to cause fetal death... whether or not the fetus is known
to exist when such substance or device is employed."' 85 The
176. Webster v. Reproductive Health Servs., 492 U.S. 490, 506 (1989).
177. Id. at 505-06.
178. See Brownfield v. Daniel Freeman Marina Hosp., 256 Cal. Rptr. 240, 244 (Ct.
App. 1989).
179. 488 F. Supp. 181 (E.D. La. 1980).
180. LA. REV. STAT. ANN. § 40:1299.35.1(1) (West 1979).
181. Margaret S., 488 F. Supp. at 191.
182. Id.
183. 627 F.2d 772 (7th Cir. 1980).
184. Id. at 789.
185. Id. (quoting S.B. 47, the Illinois Abortion Law of 1975, § 2(10) (current version
at ILL. REV. STAT. ch. 720, para. 515 (1992))).
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court held that the statute, which defined fetus as "a human
being from fertilization until birth," was overbroad because it
would include the IUD.
186
A recent California case provides further support for the
legal proposition that contraception that acts after fertilization
is not abortion. In Brownfield v. Daniel Freeman Marina Hos-
pital,8 7 the plaintiff was taken to the defendant's emergency
room after being raped.' 88 Her mother asked for information
about the morning-after pill, but the Catholic hospital refused
to provide the information. 1 9 California's abortion law states
that religious institutions may not be held liable for failure to
permit or perform an abortion. 19 0 The plaintiff, who did not
become pregnant despite not receiving the treatment, sought a
declaration that the hospital's failure to provide information
about the morning-after pill constituted failure to provide opti-
mal emergency treatment for rape victims. 191 She also sought
an injunction requiring the hospital to provide the morning-
after pill or to stop treating rape victims and instead transport
them to another emergency room.
192
The court held that California's abortion law exempting
religious institutions from participating in abortions did not
shield the hospital from liability for refusing to provide informa-
tion about the morning-after pill. 193 The court agreed with the
plaintiff that postcoital contraception is not abortion, relying in
part on Margaret S. 94 The court thus held that a rape victim
may have a cause of action when she can allege that (1) a skilled
practitioner would have provided her with information about,
and access to, postcoital contraception; (2) she would have
elected such treatment if offered; and (3) she was damaged by
the hospital's failure to provide access to the treatment.195
From a jurisprudential standpoint, postcoital contraception
is generally regarded as squarely within laws governing contra-
186. Charles, 627 F.2d at 789.
187. 256 Cal. Rptr. 240 (Ct. App. 1989).
188. Id. at 242.
189. Id.
190. CAL. HEALTH & SAFETY CODE § 25955(c) (West 1984).
191. Brownfield, 256 Cal. Rptr. at 242.
192. Id. at 242.
193. Id. at 245.
194. Id.
195. Id. In this case, the court affirmed the trial court's dismissal because the
plaintiff had not alleged facts demonstrating that her injury required equitable relief.
Id. at 245.
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ception, rather than those governing abortion. RU-486, if
approved as a postcoital contraceptive, should not be treated
differently. Because the drug's effect is similar to two fertility
control methods that the courts have repeatedly held do not
constitute abortion, treating RU-486 differently would produce
inconsistent, unprincipled law.
In addition to these legal arguments, Section C argues that
there are compelling medical reasons to approve RU-486 as a
contraceptive.
C. Medical Advantages of RU-486 as a
Postcoital Contraceptive
From a medical standpoint, RU-486 has important advan-
tages over currently used emergency contraceptives. As the
studies comparing RU-486 with the standard estrogen and
progestogen morning-after regimen have demonstrated, RU-
486 not only produces far fewer side effects, but it may also be
more effective. 196 Because it does not involve a large, concen-
trated dose of hormones, those health care practitioners who
fear the possible health effects of the current postcoital contra-
ceptive regimen may be more comfortable prescribing RU-486.
Another advantage is that, unlike the current morning-after
pill, RU-486 does not require immediate medical intervention
following unprotected intercourse. Instead, it may be taken at
any time before a woman expects her menstrual period, or even
in early pregnancy. 197 If RU-486 were to be developed as a
once-a-month pill for regular contraceptive use, it would offer
women the additional advantage of taking only twelve pills per
year, rather than over 250.198
An even more urgent medical reason to approve RU-486 as
a postcoital contraceptive is that this strategy would most
quickly make the drug available to a broad medical constitu-
ency that stands to benefit from it. Among the more pressing
health problems that RU-486 shows promise in helping to alle-
viate are breast cancer and AIDS.199 However, development of
these uses of the drug has been obstructed by the abortion
debate.20 0 The longer the drug is embroiled in a controversy at
196. See Glasier et al., supra note 2, at 1044; Trussell et al., supra note 3, at 273.
197. THE ABORTION PILL, supra note 12, at 18.
198. Djerassi, supra note 1, at 359.
199. Regelson, supra note 16, at 331-32.
200. Id. at 332..
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the regulatory level because of its use in early abortions, the
longer it will be unavailable to researchers to aid in the treat-
ment of these and other diseases and disorders. As noted above,
however, FDA approval of RU-486 for a use altogether unre-
lated to fertility control would fail to maximize the drug's most
important benefit: giving women more control over their own
fertility.
That need for control implicates policy arguments in favor
of approving RU-486 as a postcoital contraceptive. Section D
explores the policy aspects of approving RU-486 as a postcoital
contraceptive.
D. Policy Considerations: Preventing Abortion
One of the most important policy reasons to approve RU-
486 as a postcoital contraceptive is its potential in reducing the
demand for therapeutic abortion. The recent New England
Journal of Medicine study comparing RU-486 to the morning-
after pill concluded that the demand for abortion would be
reduced if family planning services that included RU-486 as a
postcoital contraceptive were widely available.20 1 Estimates
are that postcoital contraception could be used by about three-
quarters of those women whose unintended pregnancies result
from either the failure of a birth control method or from the fail-
ure to use a method properly or consistently.20 2 Family plan-
ning specialists have stated that if postcoital contraception
were widely available, the number of unintended pregnancies
could be reduced by at least 1.7 million, thereby reducing the
number of induced abortions by approximately 800,000 per
year.20 3
However, wide availability of RU-486 as a postcoital con-
traceptive would pose some problems not encountered with the
current morning-after pill. Because the current postcoital con-
traceptive regimen is likely to be physically unpleasant, women
are unlikely to rely heavily on its use as a substitute for regular
birth control. 20 4 Removing this unpleasantness could result in
increased reliance on contraception after the fact, possibly dis-
tracting women from the importance of using barrier methods
201. Glasier et al., supra note 2, at 1044.
202. Trussell et al., supra note 3, at 269.
203. Id. at 270.
204. Hoffman, supra note 22, at 15.
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not only to prevent pregnancy, but to protect themselves from
AIDS and other sexually transmitted diseases.2 °5
On the other hand, broad availability of postcoital contra-
ceptives can serve as a bridge. Following a woman's initial visit
to a doctor or clinic for emergency contraception, she can then
be counseled about and encouraged to use regular birth control.
Furthermore, health care practitioners will be able to shift a
large proportion of their energy and resources from providing
abortions to focusing on other health care services, such as the
prevention and the treatment of AIDS and other sexually trans-
mitted diseases. The fact that some people may be unable or
unwilling to plan ahead for birth control is not a reason to with-
hold or restrict use of emergency contraception. In the words of
Dr. Louise Tyrer, a vice president of Planned Parenthood, "The
medical profession does not encourage people to use the post-
coital method except in an emergency and certainly not on a
regular basis, but it's better than getting pregnant and having
an abortion."
20 6
FDA approval of RU-486 as a postcoital contraceptive
would further aid in the goal of reducing abortions by making
an emergency contraceptive available to millions of women who
rely on federally-funded clinics for their health care. Such clin-
ics are now precluded from offering the morning-after pill
because birth control pills are not FDA approved for that use.2 °7
As a matter of policy, health care that includes complete contra-
ceptive services should be available to all women, not just those
who can afford to see a private physician. In addition, giving
low-income women increased control over their fertility is criti-
cally important. Ensuring that families are planned with only
the number of children that parents can emotionally and finan-
cially care for is an important step in breaking the cycle of pov-
erty that affects millions of women and children in this country.
V. CONCLUSION
Focusing on the use of RU-486 as a postcoital contraceptive
will avoid much controversy and best serve the needs of women
and the goals of society. The drug is an important means of
fertility control that has been demonstrated to be safe and effec-
tive, and it should be made available now. The need for addi-
205. Id.
206. Arieff, supra note 24.
207. See supra notes 150-153 and accompanying text.
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tional methods of fertility control is highlighted by predictions
that the world population will increase by at least one billion
people every twenty years during the coming century.20 Dr.
Baulieu has pointed out that increasing population remains a
pressing problem, despite the recent worldwide trend toward a
slowing of the increase.2 "9
The best way to slow population growth is to reduce the
number of unintended pregnancies by giving women the best
available means to control their fertility. Wider availability of
postcoital contraceptives has the proven potential to reduce
sharply the incidence of unintended pregnancies and abortions.
President Clinton has stated, "Our vision should be of an
America where abortion is safe and legal, but rare."2 10 RU-486,
used as a postcoital contraceptive, can best help achieve that
vision.
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209. Id.
210. Clinton Signs Memoranda, supra note 34.
1993] 189
